Menu
2026 Session

Budget Amendments - HB30 (Committee Approved)

View Budget Item
View Budget Item amendments

Continue Support for Fast Acting Insulin

Item 101 #3h

Item 101 #3h

First Year - FY2027 Second Year - FY2028
Commerce and Trade
Economic Development Incentive Payments FY2027 $2,000,000 FY2028 $0 GF

Language
Page 99, line 21, strike "$79,409,579" and insert "$81,409,579".

Page 102, after line 20, insert:

"S. Out of this appropriation, $2,000,000 the first year from the general fund is provided to the Virginia Economic Development Partnership Authority (the Authority) to continue support for a non-profit operating a pharmaceutical manufacturing facility in developing a fast-acting insulin. Prior to any funds being disbursed, pursuant to the existing Memorandum of Understanding (MOU) between the non-profit and the Authority, the company shall demonstrate a match of non-state funds equal to the amount provided in this paragraph. No state funds provided in this paragraph or paragraph W., Item 101, Chapter 725, 2025 Acts of Assembly shall be provided to the company until the company has demonstrated to the satisfaction of the Authority sufficient funding estimated at $27.0 million is available to produce the fast-acting insulin. At the conclusion of the project, the company shall be required to report to the Authority on the: (i) jobs created as a result of the investment; (ii) estimated savings to residents of the Commonwealth from the purchase of low-cost insulin; and, (iii) estimated potential savings to the Commonwealth as a self-insured employer from the availability of affordable insulin manufactured at a non-profit facility in Virginia. Any balances for the purposes specified in this paragraph which are unexpended on June 30, 2027 and June 30, 2028 shall not revert to the general fund but shall be carried forward and reappropriated."



Explanation

(This amendment provides $2.0 million in fiscal year 2027 from the general fund for the Virginia Economic Development Partnership Authority to partner with a non-profit entity for the continued development of a fast-acting insulin. This funding would be in addition to $3.0 million provided from state resources for this purpose in fiscal year 2025, and allow the company to raise private resources to reach the $27.0 million needed to complete the project.)